CA2369078A1 - Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk - Google Patents

Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk Download PDF

Info

Publication number
CA2369078A1
CA2369078A1 CA002369078A CA2369078A CA2369078A1 CA 2369078 A1 CA2369078 A1 CA 2369078A1 CA 002369078 A CA002369078 A CA 002369078A CA 2369078 A CA2369078 A CA 2369078A CA 2369078 A1 CA2369078 A1 CA 2369078A1
Authority
CA
Canada
Prior art keywords
sgk
inhibitor
human cell
medicament
cell volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369078A
Other languages
French (fr)
Inventor
Florian Lang
Siegfried Waldegger
Carsten Wagner
Stefan Broer
Karin Klingel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2369078A1 publication Critical patent/CA2369078A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The invention relates to medicaments which contain inhibitors or activators of cell-volume regulated human kinase h-sgk. Medicaments of this type are suitable for treating conditions, in which an increased or reduced expression of h-sgk is identified.

Description

as originally filed Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk The present invention relates to medicaments comprising inhibitors or activators of the cell volume-regulated human kinase h-sgk. Such pharmaceuticals are suitable for the therapy of pathological states in which an increased or reduced expression of h-sgk is found. EP-0 861 896 has already described h-sgk and processes for its preparation, and the contents thereof are expressly intended also to form part of the present description.
Definitions of terms:
h-sgk: human serum and glucocorticoid dependent kinase (serine/threonine kinase) ENaC: epithelial Na+ channel MDEG: mammalian degenerin (Waldmann, R., Lazdunski, M. (1998) Current Opinion in Neurobiology 8: 418-424); a synonymous term is "BNC"
(brain Na+ channel) TGFI3i: tumor growth factor (31 NKCC: Na+, K+, 2C1- cotransporter HEPES: [4-(2-hydroxyethyl)piperazino]ethanesulfonic acid SEM: standard error of mean Trans-dominant inhibitory kinase: h-sgk modified by mutation: lysine in position 127 has been replaced by arginine (K127R); the mutation is located in the catalytic region and suppresses the catalytic function of the kinase.
An increased expression of h-sgk is often found in diabetes mellitus, arteriosclerosis, Alzheimer's disease, cirrhosis of the liver, Crohn's disease, fibrosing pancreatitis, pulmonary fibrosis and chronic bronchitis. The increased production of h-sgk can be explained by stimulation of expression by TGF13~
(fig. 1 ). Fibrotic disorders are caused by increased formation and reduced breakdown of matrix proteins. Both are effects of TGFl3l. Increased expression of the matrix proteins in fibroblasts can be suppressed by inhibiting the NKCC
with furosemide (fig. 2). It has to date been unclear whether the increased expression of h-sgk is only a consequence or is the cause of the disorder.
Surprising findings now prove h-sgk activates Na+, K+, 2C1- cotransport (fig.
3). It can be concluded from this that stimulation of NKCC by h-sgk induces fibrosis.
Besides Na+, K+, 2Cl- cotransport, h-sgk also activates ENaC (figs. 4 and 5) and MDEG.
The stimulating effect of h-sgk on ENaC can be suppressed by kinase inhibitors such as, for example, staurosporine (Sigma, D-82041 Deisenhofen) or chelerythrine (Sigma, loc. cit.) (fig. 4). In addition, the effect of h-sgk on ENaC can be suppressed, for example, by traps-dominant inhibitory kinase (fig. 5).
Inhibitors of h-sgk such as staurosporine, chelerythrine or other kinase inhibitors might therefore be employed in the therapy of the abovementioned disorders.
Generally suitable for this purpose are all known kinase inhibitors. Kinase inhibitors are also commercially available in many cases, for example from Calbiochem-Novabiochem GmbH, Listweg l, D-65812 Bad Soden (see "1998 General Catalog"). Further kinase inhibitors can be obtained from other commercial and noncommercial sources known to the skilled worker.
Expression of h-sgk is increased in an epileptic seizure. The functional data we have found show that the effects are suitable for reducing the excitability of neurons because activation of NKCC leads to a reduction in the extracellular K+
concentration, which is followed by hyperpolarization and thus inhibition of the activity of neurons. In addition, the inhibition of MDI?G ought to inhibit neuronal excitability. Accordingly, kinase activators which cross the blood-brain barrier might be employed successfully for epileptic seizures. Conversely, kinase inhibition with drugs crossing the blood-brain barrier might increase attentiveness and learning ability. Kinase activators have moreover been known to the skilled worker for a lengthy period, among which the protein kinase C activators are particularly of interest (see, for example, Calbiochem-Novabiochem 1998 General Catalog, loc. cit.). Further kinase activators can be obtained from other commercial and noncommercial sources known to the skilled worker.

Since the Na+, K+, 2C1- cotransport and the Na+ channel are crucial for renal Na+
absorption and an increased renal Na+ absorption is associated with hypertension, it must be assumed that increased expression of the kinase leads to hypertension and reduced expression of the kinase leads to hypotension.
The present invention thus also relates to the use of inhibitors of h-sgk for producing medicaments for the treatment of diabetes mellitus, arteriosclerosis, Alzheimer's disease, cirrhosis of the liver, Crohn's disease, fibrosing pancreatitis, pulmonary fibrosis, chronic bronchitis, radiation fibrosis, scleroderma, cystic fibrosis and other fibrosing disorders, and for the therapy of essential hypertension.
Medicaments comprising inhibitors or activators of h-sgk can additionally be employed to regulate neuronal excitability. It is particularly advantageous to use the inhibitors staurosporine or chelerythrine and their analogs.
RESULTS
Diabetic kidney:
Expression of h-sgk in the normal kidney is only low. A few cells in the glomerulus, late proximal and distal tubule show distinct h-sgk expression. In contrast to this, cells with massive h-sgk expression accumulate in the diabetic kidney.
Arteriosclerosis:
Cells massively expressing h-sgk are frequently found in the walls of arteriosclerotic vessels.
Alzheimer's disease:
Only a few cells expressing h-sgk are found in the normal brain. These cells are probably oligodendroglial cells. The number of h-sgk-expressing cells is significantly increased in brains with Alzheimer's disease.
Cirrhosis of the liver:
Only copper cells express h-sgk in the normal liver. However, in cirrhosis of the liver the tissue is dotted with h-sgk-expressing cells.
Crohn's disease:
In normal intestinal tissue, h-sgk is expressed exclusively in the enterocytes.
However, in Crohn's disease, the kinase is also found in connective tissue.
Fibrosing pancreatitis:
In the normal pancreas, h-sgk is found in acinar cells and in duct cells. A
few h-sgk-expressing mononuclear cells are found around the pancreatic ducts.
There is a marked increase in kinase expression in fibrosing pancreatitis.
Pulmonary fibrosis and chronic bronchitis:
Massive expression of h-sgk is observed in pulmonary fibrosis and chronic bronchitis.
Stimulation of h-sgk expression by TGF131:
The expression of h-sgk is stimulated by TGF13, (fig. 1). Since TGFl31 is produced in fibrotic/inflamed tissue, this finding explains the increased expression of h-sgk in inflamed tissue.
TGFl3~ stimulates the expression of the matrix protein biglycan, an effect which is suppressed by the NKCC inhibitor furosemide:
TGFI31 stimulates the expression of biglycan. In the presence of the NKCC
inhibitor furosemide, the effect of TGF131 on biglycan expression is completely suppressed. Thus activation of NKCC is a precondition for the fibrotic effect of TGFf3 ~ . (fig. 2).
Stimulation of NKCC by h-sgk:
The significance of the increased expression of the kinase in fibrotic tissue might be manifold and not causally connected with the fibrosis. However, experiments with the two-electrode voltage clamp have shown that the activity of NKCC is massively stimulated by h-sgk (fig. 3). In view of the furosemide sensitivity of biglycan synthesis, this finding unambiguously demonstrates a causal role of h-sgk in fibrosis.
Stimulation of ENaC by h-sgk:
This effect can be suppressed by the kinase inhibitors staurosporine and chelerythrine. As fig. 4 shows, there is a massive increase in the current with ENaC
through coexpression with h-sgk. The kinase therefore stimulates ENaC. The kinase inhibitors staurosporine and chelerythrine are able completely to suppress the activation of ENaC by h-sgk.
Stimulation of epithelial ENaC by h-sgk can be reversed by coexpression of the traps-dominant inhibitory kinase h-sgk:
As fig. 5 shows, the stimulating effect of h-sgk coexpression on the ENaC-mediated Na+ current can be suppressed by coexpression of a traps-dominant inhibitory kinase. This traps-dominant inhibitory kinase (compare with "definitions of terms") is modified on the catalytic unit in such a way that it can no longer display its function. However, since it binds to the substrate it displaces the active kinase and thus suppresses its effects. The traps-dominant inhibitory kinase not only suppresses the increase in ENaC activity due to exogenous h-sgk but evidently also suppresses the stimulation by endogenous h-sgk.
MDEG is completely blocked by coexpression with h-sgk:
As fig. 6 shows, expression of MDEG in oocytes induces a strong Na+ current which is activated by lowering the extracellular pH. The channel is completely blocked by coexpression with h-sgk. It must be concluded from this that h-sgk inhibits neuronal excitability. Examples:
Example 1: In situ hybridization Tissue from normal pancreas, liver, vessels, brain, lung, kidney and intestine, and tissue with diabetic nephropathy, arteriosclerosis, Alzheimer's disease, cirrhosis of the liver, Crohn's disease, fibrosing pancreatitis and pulmonary fibrosis was embedded in paraffin in 4% paraformaldehyde/0.1 M sodium phosphate buffer (pH 7.2) for 4 hours. Tissue sections were dewaxed and hybridized as described previously (Kandolf, R., D. Ameis, P. Kirschner, A. Canu, P.H. Hofschneider, Proc. Natl. Acad. Sci. USA 84: 6272-6276, 1987; Hohenadl, C., K. Klingel, J.
Mertsching, P. H. Hofschneider, R. Kandolf., Mol. Cell. Probes 5: 11-20, 1991;
Klingel, K., C. Hohenadl, A. Canu, M. Albrecht, M. Seemann, G. Mall, R.
Kandolf, Proc. Natl. Acad. Sci. USA, 89: 314-318, 1992).
The hybridization mixture contained either 35S-labeled sense RNA coding for h-sgk or 35S-labeled antisense RNA complementary to the latter RNA (500 ng/ml of each) in 10 mM Tris-HC1, pH 7.4; 50% (vol/vol) deionized formamide; 600 mM
NaCI; 1 mM EDTA; 0.2% polyvinylpyrrolidone; 0.02% Ficoll; 0.05% calf serum albumin; 10% dextran sulfate; 10 mM dithiothreitol; 200 ~g/ml denatured sonicated salmon sperm DNA and 100 p,g/ml rabbit liver tRNA.
Hybridization with RNA probes was carried out at 42°C for 18 hours. The slides were washed as described (Hohenadl et al., 1991; Klingel et al., 1992), and then incubated in 2x standard sodium citrate at 55°C for 1 hour.
Unhybridized single-stranded RNA probes were digested by RNase A (20 pg/ml) in 10 mM Tris-HCI, pH 8.0/0.5 M NaCI at 37°C for 30 min. Tissue samples were then autoradiographed for three weeks (Klingel et al., 1992) and stained with hematoxylin/eosin.
Example 2: Transcriptional regulation of biglycan and h-sgk Cells were cultivated in RPMI/5% C02/10 mM glucose at 37°C, pH
7.4, supplemented with 10% (vol/vol) fetal calf serum (FCS). The cells were grown to 90% confluence and then homogenized in TRIZOL (GIBCO/BRL) (about 0.4x 106 per sample). Total RNA was prepared in accordance with the manufacturer's instructions. Northern blots were fractionated by electrophoresis through 10 g/1 agarose gels with 15 or 20 ~g of total RNA with separate control in the presence of 2.4 mol/1 formaldehyde. RNA was transferred by vacuum (Appligene Oncor Trans 2o- DNA Express Vacuum Blotter, Appligine, Heidelberg, Germany) to positively charged nylon membranes (Boehringer Mannheim, Germany) and crosslinked under ultraviolet light (UV Stratalinker 2400, Stratagene, Heidelberg, Germany).
Hybridization was carried out over night with DIG-Easy-Hyb (Boehringer Mannheim) at a probe concentration of 25 pg/1 at 50°C. The digoxigenin (DIG)-labeled probes were produced by PCR as described in detail earlier (Waldegger et al. (1997) PNAS 94: 4440-4445). For the autoradiography, the filters were exposed to an X-ray film (Kodak) for an average of S min.
Example 3: Two-electrode voltage clamp and tracer flux experiments Dissection of Xenopus laevis, and the obtaining and treatment of the oocytes has been described in detail earlier (Busch et al. 1992). The oocytes were each injected with 1 ng of cRNA of NKCC, ENaC or MDEG with or without simultaneous injection of h-sgk. It was possible to carry out two-electrode voltage and current clamp experiments 2-8 days after the injection. Na+ influx which could be inhibited by furosemide through the NKCC was measured by the 22Na+ uptake, which was determined with a scintillation counter, into the oocytes. Na+ currents (ENaC) were -filtered at 10 Hz and recorded with a pen recorder. The experiments were normally carried out on the second day after cRNA injection. The bath solution contained:
96 mM NaCI, 2 mM KCI, 1.8 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES at pH 7.5 and the holding potential was -50 mV. The pH was adjusted by titration with HCl or NaOH in all the experiments. The flow rate of the bath liquid was set at 20 ml/min, which ensured a complete change of solution in the measurement chamber within 10-15 s. All the data are stated in the form of arithmetic means ~
SEM.
Figure legends:
Fig. 1: Stimulation of h-sgk expression by TGF13~:
The expression of h-sgk is stimulated by TGF13~. The effect of TGF131 after 0.5 to 6 h is shown (top). The phorbol ester PDD (4-alpha-phorbol 12,13-didecanoate; stimulates protein kinase C) and the Cap ionophore ionomycin (Sigma, loc. cit; increases the intracellular Ca++ concentration) likewise stimulate h-sgk expression (below).
Fig. 2: Stimulation of biglycan expression by TGFI3,:
The expression of biglycan (B) is stimulated by osmotic swelling of cells (hypo = h, top left) and by TGFf31 (top right). The effect of TGF131 on biglycan expression is almost completely suppressed in the presence of the NKCC inhibitor bumetanide (b) (control = c).
Fig. 3: Stimulation of the NKCC by h-sgk:
The uptake which can be inhibited by furosemide of 22Na+ in oocytes [uptake (nmo1/20 min/oocyte) = u] which express the NKCC is massively stimulated by h-sgk. NKCC-injected oocytes do not show a higher Na+
influx than uninfected oocytes (n.i.). This Na+ influx is not inhibited by the NKCC inhibitor furosemide (= F) (top). Expression of h-sgk alone does not lead to stimulation of the Na+ influx. Coexpression of h-sgk with NKCC
leads to a large increase in the Na+ influx, and this increase is completely suppressed by furosemide (below).
Fig. 4: Stimulation of the ENaC by h-sgk:
The current through the ENaC (I) increases massively through coexpression with h-sgk. Treatment of the oocytes with the kinase inhibitors -g-staurosporine (S) or chelerythrine (C) suppresses the activation of the Na+
channel by h-sgk.
Fig. 5: The stimulation of the ENaC by h-sgk can be reversed by coexpression of the trans-dominant inhibitory kinase:
oocytes expressing ENaC and h-sgk simultaneously show very much larger currents (I) than do oocytes expressing only the ENaC. Coexpression of the trans-dominant inhibitory kinase suppresses the stimulation of the ENaC by h-sgk.
Fig. 6: Inhibition of the MDEG by h-sgk:
The current through the MDEG (I) increases with the duration of the incubation [day (T) 1-4]. The current is completely suppressed by coexpression with h-sgk (peak = p; plateau = pl).

Claims (18)

1. A medicament comprising an inhibitor of the human cell volume-regulated kinase hsgk for the therapy of hypertension with reduction of the activity of the epithelial sodium channel (ENaC).
2. A medicament as claimed in claim 1, which comprises chelerythrine as inhibitor.
3. A medicament comprising an inhibitor of the human cell volume-regulated kinase hsgk for the therapy of at least one of the disorders from the group of cirrhosis of the liver, fibrosing pancreatitis, pulmonary fibrosis, radiation fibrosis, scleroderma, cystic fibrosis and chronic bronchitis with reduction of the activity of the epithelial sodium channel (ENaC) and/or of the Na+, K+,2 Cl- cotransporter (NKCC).
4. A medicament as claimed in claim 3, which comprises staurosporine as inhibitor.
5. A medicament as claimed in claim 3, which comprises chelerythrine as inhibitor.
6. A medicament comprising an activator of the human cell volume-regulated kinase hsgk with activation of the Na+, K+, 2 Cl- cotransporter (NKCC) and/or with inhibition of the brain-specific sodium channel MDEG for the treatment of epilepsy.
7. The use of an inhibitor of the human cell volume-regulated kinase hsgk for producing a medicament for the treatment of hypertension with reduction of the activity of the epithelial sodium channel (ENaC).
8. The use of chelerythrine as inhibitor as claimed in claim 7.
9. The use of an inhibitor of the human cell volume-regulated kinase hsgk for producing a medicament for the treatment of at least one of the disorders from the group of cirrhosis of the liver, fibrosing pancreatitis, pulmonary fibrosis, radiation fibrosis, scleroderma, cystic fibrosis and chronic bronchitis with reduction of the activity of the epithelial sodium channel (ENaC) and/or of the Na+, K+, 2 Cl- cotransporter (NKCC).
10. The use of staurosporine as inhibitor as claimed in claim 9.
11. The use of chelerythrine as inhibitor as claimed in claim.
12. The use of an activator of the human cell volume-regulated kinase hsgk for producing a medicament for the treatment of epilepsy with activation of the Na+, K+, 2 Cl- cotransporter (NKCC) and/or with inhibition of the brain-specific sodium channel (MDEG).
13. The use of inhibitors of the epithelial sodium channel (ENaC) and/or of the Na+, K+, 2 Cl- cotransporter (NKCC) for producing a medicament for the treatment of hypertension and/or at least one of the disorders from the group of cirrhosis of the liver, fibrosing pancreatitis, pulmonary fibrosis, radiation fibrosis, scleroderma, cystic fibrosis and chronic bronchitis.
14. The use of the quantitative detection of the human cell volume-regulated kinase hsgk for diagnosing hypertension/hypotension.
15. The use of the quantitative detection of the human cell volume-regulated kinase hsgk for diagnosing at least one of the disorders from the group of fibrosing pancreatitis, radiation fibrosis, scleroderma, cystic fibrosis, chronic bronchitis and epilepsy.
16. A kit for carrying out a quantitative detection of the human cell volume-regulated kinase hsgk as claimed in at least one of claims 14 and 15.
17. A method for identifying inhibitors of the human cell volume-regulated kinase hsgk, in which the modulation of the activity of the epithelial sodium channel (ENaC) and/or of the brain-specific sodium channel (MDEG) and/or the modulation of the activity of the Na+, K+, 2 Cl- cotransporter (NKCC) is measured.
18. An inhibitor of the human cell volume-regulated kinase hsgk which can be identified by a method as claimed in claim 17.
CA002369078A 1999-04-20 2000-04-19 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk Abandoned CA2369078A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19917990A DE19917990A1 (en) 1999-04-20 1999-04-20 Medicament containing inhibitors of cell volume regulated human kinase h-sgk
DE19917990.5 1999-04-20
PCT/EP2000/003578 WO2000062781A1 (en) 1999-04-20 2000-04-19 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk

Publications (1)

Publication Number Publication Date
CA2369078A1 true CA2369078A1 (en) 2000-10-26

Family

ID=7905297

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369078A Abandoned CA2369078A1 (en) 1999-04-20 2000-04-19 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk

Country Status (18)

Country Link
EP (1) EP1171131A1 (en)
JP (1) JP2002542196A (en)
KR (1) KR100718900B1 (en)
CN (1) CN1351496A (en)
AU (1) AU779941B2 (en)
BR (1) BR0009914A (en)
CA (1) CA2369078A1 (en)
CZ (1) CZ20013778A3 (en)
DE (1) DE19917990A1 (en)
HU (1) HUP0200819A3 (en)
MX (1) MXPA01010588A (en)
NO (1) NO20015054L (en)
PL (1) PL198427B1 (en)
RU (1) RU2288718C9 (en)
SK (1) SK14972001A3 (en)
UA (1) UA79066C2 (en)
WO (1) WO2000062781A1 (en)
ZA (1) ZA200108610B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042137A1 (en) * 2000-08-28 2002-03-14 Florian Lang sgk2 and sgk3 as diagnostic and therapeutic targets
DE10113876A1 (en) * 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnosis of genetically related hypertension, by correlating blood pressure with overexpression or modification of human sgk family proteins
ATE439797T1 (en) * 2001-04-27 2009-09-15 Cold Spring Harbor Lab RELIEF OF MEMORY DEFICIT AND MEMORY COMPONENTS OF PSYCHIATRIC FUNCTIONAL DISORDERS BY ALTERING ATYPICAL PKM ACTIVITY
DE10149393A1 (en) * 2001-09-28 2003-04-24 Florian Lang Detecting the expression of serum and glucocorticoid-dependent kinase-1 (sgk1), for diagnosing coagulative diseases, diabetes, tumors, diabetes and autoimmune diseases, comprises using an antibody against sgk1
DE10225844A1 (en) * 2002-06-04 2003-12-18 Lang Florian sgk and nedd as diagnostic and therapeutic targets
DE10305212A1 (en) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Use of the sgk gene family for the diagnosis and therapy of cataracts and glaucoma
BR0318166A (en) * 2003-03-03 2006-04-04 Florian Lang use of a sgk1 detection substance, detection kit, as well as a pharmaceutical composition that inhibits or activates its expression and / or function
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
DE10346913A1 (en) * 2003-10-09 2005-05-04 Merck Patent Gmbh acylhydrazone
WO2005084702A1 (en) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. Agent for preventing and treating organ fibrosis
WO2005094796A2 (en) * 2004-03-11 2005-10-13 Merck Patent Gmbh Methods for interfering with fibrosis
MXPA06010268A (en) * 2004-03-11 2007-04-23 Merck Patent Gmbh Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases.
US20090136920A1 (en) * 2004-04-30 2009-05-28 Stefan Golz Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
DE102004030987A1 (en) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituted (3-hydroxyphenyl) -acetic acid benzylidene hydrazides
MX2007001155A (en) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network.
DE102005001053A1 (en) * 2005-01-07 2006-07-20 Merck Patent Gmbh Square acid derivatives
DE102005015255A1 (en) 2005-04-04 2006-10-05 Merck Patent Gmbh New acylhydrazide compounds are signal transduction kinase inhibitor, useful for treating and/or preventing diseases, e.g. diabetes, adiposity, metabolic syndrome, cancer and tumor cells
DE102005035742A1 (en) * 2005-07-29 2007-02-01 Merck Patent Gmbh New cyclobut-3-ene-1,2-dione derivatives are kinase inhibitors useful for treating e.g. cancer, hypertension, diabetes, glaucoma and bacterial infections
DE102005039541A1 (en) * 2005-08-22 2007-03-22 Merck Patent Gmbh 3-oxo-indazol-square acid derivatives
DE102007002717A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
DE102007022565A1 (en) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclic indazole derivatives
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
DE102008010363A1 (en) 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 as a therapeutic and diagnostic target for carcinomatous diseases
DE102008010361A1 (en) 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1 inhibitors for the prophylaxis and / or therapy of viral diseases and / or carcinomas
DE102008010362A1 (en) * 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 as a therapeutic and diagnostic target for viral diseases
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
DE102008038220A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh oxadiazole
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
DE102008059133A1 (en) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorophenyl diacylhydrazide derivatives
EP2662078A1 (en) 2010-11-10 2013-11-13 National Jewish Health Methods to Treat Allergic Conditions
CN107875153A (en) * 2017-11-16 2018-04-06 上海壹志医药科技有限公司 The medicinal usage of Des-N-methylchelerythrine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5874464A (en) * 1995-01-13 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Conformationally constrained diacylglycerol analogues
WO1997007081A2 (en) * 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
PT906268E (en) * 1996-05-30 2002-05-31 Aventis Pharma Inc FLUORENONES WITH SUBSTITUTIONAL ALKYLOXYAMINE AND ITS USE AS PROTEIN KINASE C INHIBITORS
EP0887081B1 (en) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
CO4940430A1 (en) * 1997-07-07 2000-07-24 Novartis Ag POLYCLIC COMPOUNDS CONTAINING HYDROGENATED STAUROSPORIN WITH CONVENIENT PHARMACOLOGICAL PROPERTIES AND AN INHIBITING EFFECT ON THE GROWTH OF TUMOR CELLS

Also Published As

Publication number Publication date
NO20015054L (en) 2001-12-14
KR100718900B1 (en) 2007-05-17
AU4297200A (en) 2000-11-02
WO2000062781A1 (en) 2000-10-26
PL198427B1 (en) 2008-06-30
NO20015054D0 (en) 2001-10-17
CN1351496A (en) 2002-05-29
PL352547A1 (en) 2003-08-25
BR0009914A (en) 2002-01-08
ZA200108610B (en) 2002-01-02
HUP0200819A2 (en) 2002-07-29
SK14972001A3 (en) 2002-06-04
UA79066C2 (en) 2007-05-25
AU779941B2 (en) 2005-02-17
CZ20013778A3 (en) 2002-06-12
RU2288718C2 (en) 2006-12-10
HUP0200819A3 (en) 2009-08-28
MXPA01010588A (en) 2004-09-06
RU2288718C9 (en) 2008-04-27
JP2002542196A (en) 2002-12-10
DE19917990A1 (en) 2000-11-02
KR20020012172A (en) 2002-02-15
EP1171131A1 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
AU779941B2 (en) Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
EP3389725B1 (en) Compositions and methods for treatment of central nervous system diseases
US6887853B2 (en) Use of geldanamycin and related compounds for treatment of fibrogenic disorders
US6214569B1 (en) Methods for screening for inhibitors of Alzheimer β-peptide filament formation
Kato et al. Mechanisms of altered Ca2+ signalling in transformed lymphoblastoid cells from patients with bipolar disorder
US20150119327A1 (en) Drug screening platform for rett syndrome
Tagashira et al. Diverse regulation of IP3 and ryanodine receptors by pentazocine through σ1-receptor in cardiomyocytes
WO2003026576A2 (en) Induction of brown adipocytes by transcription factor nfe2l2
US5434086A (en) Method of testing potential cystic fibrosis treating compounds using cells in culture
Puro et al. Characterization of an L-type calcium channel expressed by human retinal Müller (glial) cells
US20050064501A1 (en) Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk
US5888982A (en) Regulation of vascular smooth muscle cell heme oxygenase-1
Zhu et al. Progranulin deficiency leads to enhanced age-related cardiac hypertrophy through complement C1q-induced β-catenin activation
US5700640A (en) Inducers of gamma globin gene expression and screening assays therefor
Falin et al. A role for ERK1/2 in EGF-and ATP-dependent regulation of amiloride-sensitive sodium absorption
Carrió et al. A1 demonstrates restricted tissue distribution during embryonic development and functions to protect against cell death.
Maione et al. Ca2+ dysregulation in cardiac stromal cells sustains fibro-adipose remodeling in Arrhythmogenic Cardiomyopathy and can be modulated by flecainide
Nicolas et al. A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics
Shen et al. Interaction of caveolin‐1, nitric oxide, and nitric oxide synthases in hypoxic human SK‐N‐MC neuroblastoma cells
Toutenhoofd et al. Regulation of calmodulin mRNAs in differentiating human IMR-32 neuroblastoma cells
US20120232121A1 (en) Use of sarcoplasmic ca2+-atpase type 2 protein for diagnosing and treating learning or mental disorders
US20210145783A1 (en) Compositions and Methods for Treating Sickle Cell Disease
US20210236438A1 (en) Compounds and methods for the treatment of autism spectrum disorder and other neurological or psychiatric disorders
Lin et al. Chaperone-mediated autophagy is an overlooked pathway for mutant α1-antitrypsin Z degradation
Poetsch Regulation of cardiac protein quality control by deubiquitinating enzymes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued